-44.3%
CHWY vs GSK
+65.8%
-110.1%
-87.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.3% | -0.1% | -4.1% | -4.2% |
| 7D | -13.4% | -5.3% | -8.1% | -12.4% |
| 30D | -8.6% | -3.7% | -4.9% | -7.8% |
| 3M | -18.3% | -7.3% | -11.1% | -17.1% |
| 6M | -3.3% | -4.2% | +0.9% | -2.6% |
| YTD | -41.0% | +0.9% | -41.9% | -41.3% |
| 1Y | -41.1% | +7.3% | -48.4% | -42.1% |
| 3Y | -5.2% | +52.7% | -58.0% | -15.3% |
| 5Y | -73.3% | +40.1% | -113.4% | -75.9% |
| All | -44.3% | +65.8% | -110.1% | -52.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling